Shukra [SHUKRAPHAR] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Shukra
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Shukra wins in 9 metrics, Aarti Drugs wins in 10 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Shukra | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 83.45 | 23.66 | Aarti Drugs |
| Price-to-Book Ratio | 13.11 | 3.26 | Aarti Drugs |
| Debt-to-Equity Ratio | 6.65 | 44.92 | Shukra |
| PEG Ratio | N/A | -20.91 | N/A |
| EV/EBITDA | 49.17 | 17.18 | Aarti Drugs |
| Profit Margin (TTM) | 26.02% | 7.80% | Shukra |
| Operating Margin (TTM) | 53.21% | 10.11% | Shukra |
| EBITDA Margin (TTM) | 53.21% | 10.11% | Shukra |
| Return on Equity | 15.90% | 12.28% | Shukra |
| Return on Assets (TTM) | 10.58% | 6.53% | Shukra |
| Free Cash Flow (TTM) | $51.75M | $674.20M | Aarti Drugs |
| Dividend Yield | 7.26% | 0.22% | Shukra |
| 1-Year Return | 193.29% | -1.49% | Shukra |
| Price-to-Sales Ratio (TTM) | 21.85 | 1.84 | Aarti Drugs |
| Enterprise Value | $8.33B | $50.81B | Aarti Drugs |
| EV/Revenue Ratio | 22.63 | 2.10 | Aarti Drugs |
| Gross Profit Margin (TTM) | 86.72% | 36.77% | Shukra |
| Revenue per Share (TTM) | $1 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $0.22 | $20.65 | Aarti Drugs |
| Beta (Stock Volatility) | 0.33 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Shukra vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Shukra | -1.98% | -9.47% | -9.78% | 51.86% | -16.36% | 28.30% |
| Aarti Drugs | -0.48% | -0.75% | 3.34% | 14.24% | 24.23% | 7.44% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Shukra | 193.29% | 295.69% | 1,717.82% | 1,019.51% | 394.88% | 394.88% |
| Aarti Drugs | -1.49% | 9.58% | -37.53% | 209.83% | 2,685.43% | 2,351.90% |
Performance & Financial Health Analysis: Shukra vs Aarti Drugs
| Metric | SHUKRAPHAR | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹8.04B | ₹44.59B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 91,148 | 240,472 |
| 90 Day Avg. Volume | 190,256 | 684,255 |
| Last Close | ₹18.36 | ₹489.40 |
| 52 Week Range | ₹5.75 - ₹27.15 | ₹312.00 - ₹635.00 |
| % from 52W High | -32.38% | -22.93% |
| All-Time High | ₹27.15 (Mar 03, 2025) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -32.38% | -52.34% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.30% | 0.06% |
| Quarterly Earnings Growth | 0.35% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.08% |
| Operating Margin (TTM) | 0.53% | 0.10% |
| Return on Equity (TTM) | 0.16% | 0.12% |
| Debt to Equity (MRQ) | 6.65 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1.40 | ₹149.84 |
| Cash per Share (MRQ) | ₹0.27 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹79.18M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹41.04M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | 7.26% | 0.22% |
| Last 12-Month Dividend | ₹1.00 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Shukra vs Aarti Drugs
| Metric | SHUKRAPHAR | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 83.45 | 23.66 |
| Forward P/E | N/A | 15.06 |
| PEG Ratio | N/A | -20.91 |
| Price to Sales (TTM) | 21.85 | 1.84 |
| Price to Book (MRQ) | 13.11 | 3.26 |
| Market Capitalization | ||
| Market Capitalization | ₹8.04B | ₹44.59B |
| Enterprise Value | ₹8.33B | ₹50.81B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 22.63 | 2.10 |
| Enterprise to EBITDA | 49.17 | 17.18 |
| Risk & Other Metrics | ||
| Beta | 0.33 | 0.21 |
| Book Value per Share (MRQ) | ₹1.40 | ₹149.84 |
Financial Statements Comparison: Shukra vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SHUKRAPHAR | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹132.70M | ₹6.77B |
| Cost of Goods Sold | ₹17.63M | ₹4.37B |
| Gross Profit | ₹115.07M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹63.76M | ₹784.50M |
| EBITDA | ₹87.85M | ₹951.90M |
| Pre-Tax Income | ₹75.70M | ₹711.50M |
| Income Tax | ₹21.84M | ₹83.80M |
| Net Income (Profit) | ₹53.86M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SHUKRAPHAR | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | N/A | ₹45.80M |
| Total Current Assets | ₹654.27M | ₹13.38B |
| Total Current Liabilities | ₹172.84M | ₹8.37B |
| Long-Term Debt | ₹31.13M | ₹2.86B |
| Total Shareholders Equity | ₹628.36M | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹193.97M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SHUKRAPHAR | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SHUKRAPHAR | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 91,148 | 240,472 |
| Average Daily Volume (90 Day) | 190,256 | 684,255 |
| Shares Outstanding | 437.88M | 91.27M |
| Float Shares | 47.92M | 35.46M |
| % Held by Insiders | 0.89% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Shukra vs Aarti Drugs
| Metric | SHUKRAPHAR | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹1.00 |
| Last 12-Month Dividend Yield | 7.26% | 0.22% |
| 3-Year Avg Annual Dividend | ₹0.35 | ₹1.00 |
| 3-Year Avg Dividend Yield | 5.23% | 0.23% |
| 3-Year Total Dividends | ₹1.04 | ₹3.00 |
| Ex-Dividend Date | Sep 23, 2024 | Feb 04, 2025 |